Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Lantheus ( (LNTH) ).
Lantheus Holdings, Inc. has announced a definitive agreement to acquire Life Molecular Imaging Ltd. for $350 million upfront, with potential additional payments, to enhance its Alzheimer’s disease radiodiagnostic capabilities. This acquisition is expected to strengthen Lantheus’ leadership in the radiopharmaceutical space by expanding its commercial infrastructure, R&D capabilities, and radiodiagnostic pipeline, with the transaction anticipated to be accretive to adjusted EPS within 12 months of closing.
More about Lantheus
Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company that specializes in providing innovative diagnostic and therapeutic solutions to improve patient outcomes. The company operates primarily in the radiopharmaceutical industry, offering products such as Neuraceq, a PET imaging agent used to detect beta-amyloid plaques in patients with cognitive impairment, including Alzheimer’s disease.
YTD Price Performance: 7.97%
Average Trading Volume: 1,060,151
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.67B
See more insights into LNTH stock on TipRanks’ Stock Analysis page.
